Fludeoxyglucose F18

The standard adult dose of Fludeoxyglucose F-18 typically ranges from 5 to 10 mCi (185 to 370 MBq). The exact dose is calculated based on the patient's body weight, the specific type of PET scanner being used, and the clinical indication. For oncological and neurological imaging, the dose is usually administered as a single intravenous bolus injection. In cardiology, the dose is similar but may be administered following a 'glucose loading' protocol to ensure the heart muscle is actively using sugar at the time of the scan.

Fludeoxyglucose F-18 is approved for use in pediatric patients. The dosage for children is significantly lower than for adults and is strictly calculated based on body weight (typically 0.1 to 0.15 mCi per kilogram of body weight). The goal in pediatric imaging is to use the 'ALARA' principle (As Low As Reasonably Achievable) to minimize radiation exposure while still obtaining a clear diagnostic image. Healthcare providers use specialized pediatric dosing charts to ensure safety.

Renal Impairment

Because Fludeoxyglucose F-18 is primarily excreted through the kidneys, patients with renal impairment (kidney disease) require special consideration. While the dose itself might not always be reduced, the radiation stays in the body longer if the kidneys cannot flush it out. These patients are often encouraged to drink extra fluids and void (urinate) frequently after the procedure to reduce the radiation dose to the bladder.

Hepatic Impairment

No specific dosage adjustments are required for patients with hepatic (liver) impairment, as the liver does not play a major role in the elimination of this tracer.

Elderly Patients

In elderly patients, no specific dose adjustments are typically required based on age alone. However, clinicians must account for the higher likelihood of reduced kidney function and pre-existing conditions like diabetes, which can interfere with the scan results.

Fludeoxyglucose F-18 is administered only by trained nuclear medicine professionals in a clinical setting. However, the patient has several critical responsibilities to ensure the 'medication' works correctly:

1. 1Fasting: Patients must typically fast (no food or drink except plain water) for at least 4 to 6 hours before the injection. This is because high levels of natural blood sugar or insulin will compete with the FDG tracer, making the scan unreadable.
2. 2Blood Sugar Control: For patients with diabetes, blood glucose levels should ideally be below 200 mg/dL. If blood sugar is too high, the tracer cannot enter the cells effectively.
3. 3Physical Activity: Patients must avoid strenuous exercise for 24 hours before the scan. Exercise causes the tracer to go into the muscles instead of the areas the doctor needs to see.
4. 4The Uptake Period: After the injection, the patient must sit or lie quietly in a dark room for 30 to 60 minutes. Talking, reading, or moving around can cause the tracer to accumulate in the throat or muscles, which can interfere with the diagnosis.
5. 5Storage: This agent is not stored by patients. It is stored at the facility in lead-shielded containers at room temperature and must be used within hours of production.

Since Fludeoxyglucose F-18 is administered for a scheduled diagnostic procedure, a 'missed dose' in the traditional sense is not possible. However, if a patient is late for their appointment, the dose may 'decay' (lose its radioactivity) to the point where it is no longer useful. In such cases, the procedure must be rescheduled, and a new dose must be ordered from the radiopharmacy.

An overdose of Fludeoxyglucose F-18 is extremely rare due to the strict controls in nuclear medicine. If an excessive dose were given, the primary concern would be increased radiation exposure. The treatment for an overdose involves 'forced diuresis'—encouraging the patient to drink large amounts of fluids and urinate frequently to flush the tracer out of the system as quickly as possible. Emergency measures for radiation toxicity are generally not required for the doses used in PET imaging.

> Important: Follow your healthcare provider's dosing instructions and pre-scan preparations carefully. Failure to fast or rest properly can result in an inaccurate scan and the need for a repeat procedure.

Fludeoxyglucose F-18 is generally very well tolerated, and most patients experience no side effects at all. Because it is a glucose analog and administered in such tiny chemical amounts (nanograms), it does not produce the 'drug effects' associated with traditional medications. However, the most common 'side effect' is actually related to the administration process:

• Injection Site Discomfort: A small number of patients may feel a brief stinging, coldness, or warmth at the site of the IV injection. This usually disappears within minutes.
• Feeling of Claustrophobia: While not a side effect of the drug itself, many patients feel anxiety or discomfort during the 30-45 minute PET scan inside the machine.

• Headache: Some patients report a mild headache following the procedure. It is unclear if this is due to the FDG or the stress and fasting required for the scan.
• Nausea: Very rarely, patients may feel slight stomach upset. This is typically transient and resolves without treatment.
• Dizziness: A feeling of lightheadedness may occur, often associated with fasting and low blood sugar rather than the radioactive tracer itself.

• Hypersensitivity Reactions: Although extremely rare, some patients may experience a mild allergic reaction, characterized by a skin rash, itching, or hives (urticaria).
• Hypotension: A slight, temporary drop in blood pressure has been noted in very rare clinical reports.

While Fludeoxyglucose F-18 is exceptionally safe, any medical procedure involving an injection carries a minute risk of serious reactions.

> Warning: Stop taking Fludeoxyglucose F-18 (inform your technician) and call your doctor immediately if you experience any of these:

• Anaphylaxis: Signs include swelling of the face, lips, or tongue; difficulty breathing; severe wheezing; or a rapid, weak pulse. This is a life-threatening allergic reaction.
• Severe Extravasation: If the tracer leaks out of the vein and into the surrounding tissue (extravasation), it can cause localized tissue irritation or, in theory, a concentrated radiation dose to that small area. Inform the technician if you feel intense burning at the injection site.
• Severe Hyperglycemia/Hypoglycemia: In diabetic patients, the stress of the procedure or the fasting requirements may cause dangerous shifts in blood sugar levels.

The primary long-term concern with any radiopharmaceutical is the cumulative risk of radiation-induced cancer. Every PET scan contributes a small amount of ionizing radiation to the patient's lifetime total. For a standard FDG-PET scan, the effective radiation dose is approximately 7 to 8 millisieverts (mSv), which is roughly equivalent to the amount of natural background radiation a person receives over 2 to 3 years. While the risk from a single scan is very low, multiple scans over many years increase the theoretical risk of developing a secondary malignancy. Healthcare providers always weigh this theoretical long-term risk against the immediate need to diagnose or treat a life-threatening disease like cancer.

As of 2026, the FDA has not issued any Black Box Warnings for Fludeoxyglucose F-18. It is considered one of the safest diagnostic agents in modern medicine when used according to established protocols.

Report any unusual symptoms to your healthcare provider or the nuclear medicine staff immediately following your injection.

Fludeoxyglucose F-18 is a radioactive material and must be handled with specialized safety precautions. Patients should be aware that for a few hours after the injection, they will be emitting a small amount of radiation. While this is not considered dangerous to the general public, most clinics recommend avoiding prolonged close contact with pregnant women or small infants for about 12 hours after the scan.

No FDA black box warnings for Fludeoxyglucose F-18.

• Allergic Reactions: While FDG is a glucose analog, the formulation contains other ingredients. Patients with a known hypersensitivity to any component of the injection should inform their doctor. Facilities are always equipped with emergency kits to treat anaphylaxis.
• Radiation Risk: Like all radiopharmaceuticals, Fludeoxyglucose F-18 contributes to a patient’s overall long-term cumulative radiation exposure. This is particularly important in pediatric patients and those requiring frequent follow-up scans. Clinicians follow the ALARA (As Low As Reasonably Achievable) protocol.
• Extravasation Risk: If the drug is injected outside the vein, it can lead to localized radiation exposure and poor image quality. The injection site should be monitored for redness or swelling.
• Blood Glucose Interference: The most significant precaution is the patient's blood sugar level. High blood glucose (hyperglycemia) can 'out-compete' the FDG, leading to a 'false negative' scan where a tumor does not show up because it was saturated with regular sugar.

• Blood Glucose Testing: Almost all patients will have their blood sugar checked via a finger-stick test immediately before the FDG injection. If the level is too high (usually >200 mg/dL), the scan may be postponed.
• Renal Function: Patients with known kidney disease may have their Creatinine or GFR (Glomerular Filtration Rate) checked. While FDG is not nephrotoxic (it doesn't hurt the kidneys), poor kidney function slows the clearance of the radiation.
• Post-Scan Monitoring: Patients are typically observed for 15-30 minutes after the scan to ensure no immediate allergic reactions occur.

Fludeoxyglucose F-18 does not cause sedation or cognitive impairment. However, the fasting required for the scan can make some patients feel lightheaded or weak. If you feel faint due to lack of food, you should not drive until you have eaten a meal and feel stable. Most patients can drive themselves home immediately after the procedure.

There is no direct chemical interaction between Fludeoxyglucose F-18 and alcohol. However, alcohol consumption can significantly alter blood sugar levels and liver metabolism. Patients are strictly advised to avoid alcohol for at least 24 hours before their PET scan to ensure the metabolic data collected is accurate.

Fludeoxyglucose F-18 is a single-use diagnostic agent. There are no tapering requirements or withdrawal syndromes. Once the procedure is complete and the radiation has decayed (within 24 hours), the drug is gone from the system.

> Important: Discuss all your medical conditions, especially diabetes and kidney disease, with your healthcare provider before starting Fludeoxyglucose F-18.

There are no medications that are 'contraindicated' in the sense that they will cause a toxic chemical reaction with Fludeoxyglucose F-18. However, certain drugs can make the PET scan medically useless by interfering with glucose distribution.

• Insulin: Patients must not take rapid-acting insulin immediately before or during the FDG uptake period. Insulin drives glucose (and the FDG tracer) into muscle and fat cells rather than tumor cells. This creates 'muscle uptake' on the scan, which can hide cancer or look like a false abnormality. Usually, insulin must be timed several hours away from the scan.

• Corticosteroids (e.g., Prednisone, Dexamethasone): These medications increase blood glucose levels and decrease the sensitivity of the PET scan. Doctors may ask patients to withhold or adjust their steroid dose on the day of the scan.
• Colony-Stimulating Factors (e.g., Neupogen, Neulasta): These drugs stimulate bone marrow production. If a patient has recently taken these, the PET scan will show intense FDG uptake in the bones. This is a 'pharmacodynamic interaction' that can be mistaken for bone cancer. Scans are typically scheduled at least 5-7 days after the last dose of these medications.

• Metformin: While Metformin helps control blood sugar, it can cause intense FDG uptake in the intestines (bowel). This can make it difficult for radiologists to see tumors in the abdomen. Some centers ask patients to stop Metformin for 24-48 hours before the scan.
• Beta-Blockers: In some cases, beta-blockers can reduce 'brown fat' uptake of FDG, which is actually helpful for the scan. However, they should only be used if already prescribed.

• Sugar and Carbohydrates: Consuming sugar, bread, pasta, or fruit within 6 hours of the scan will raise insulin levels and ruin the image quality. This is the most critical 'interaction' for FDG.
• Caffeine: Caffeine can increase muscle activity and alter heart rate, potentially affecting the distribution of the tracer. Patients are usually told to avoid coffee, tea, and soda for 24 hours.
• High-Fat Meals: Some cardiac PET protocols actually require a high-fat, low-carb meal the night before to 'switch' the heart's metabolism, but for oncology, this is usually avoided.

• Glucosamine Supplements: Since glucosamine is a sugar-like molecule, there is a theoretical concern it could interfere with FDG uptake, although this is not well-documented in clinical trials. Most providers recommend stopping all non-essential supplements 24 hours prior.
• St. John's Wort: No known interaction, as FDG does not use the CYP34A pathway.

• Blood Glucose Monitoring: The presence of Fludeoxyglucose F-18 does not interfere with standard glucose meters, as the chemical amount of FDG is too small to register as 'sugar.'
• Thyroid Function Tests: Radioactive tracers can sometimes interfere with subsequent nuclear medicine tests (like a thyroid scan). It is usually recommended to wait 24-48 hours between different types of nuclear medicine procedures.

For each major interaction, the mechanism is usually pharmacodynamic (changing how the body handles glucose) rather than pharmacokinetic (changing how the drug is broken down). The clinical consequence is a 'non-diagnostic' or 'false' scan result. Management always involves careful timing of medications around the scan appointment.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for diabetes or inflammation.

There are very few absolute contraindications for Fludeoxyglucose F-18 because it is a diagnostic tool used in life-threatening situations. However, the following apply:

1. 1Severe Hypersensitivity: If a patient has had a documented, life-threatening anaphylactic reaction to Fludeoxyglucose F-18 in the past, they should not receive it again. The mechanism is an immune-mediated response to the tracer or its stabilizing buffers.
2. 2Pregnancy (Relative vs. Absolute): While not an absolute contraindication in a life-saving situation, pregnancy is a major deterrent. Ionizing radiation can interfere with fetal development (teratogenesis), especially in the first trimester. A pregnancy test is typically required for all females of childbearing age before administration.

Relative contraindications require a 'risk-benefit' analysis by the physician:

• Uncontrolled Diabetes: If a patient's blood sugar is consistently above 250-300 mg/dL, the FDG-PET scan will likely be of such poor quality that the radiation risk outweighs the diagnostic benefit. The procedure should be delayed until blood sugar is better managed.
• Severe Renal Failure: Patients with an eGFR below 30 mL/min will have very slow clearance of the tracer. This increases the radiation dose to the bladder and kidneys. The scan can still be performed, but the patient must be hydrated aggressively.
• Inflammation/Recent Surgery: Recent surgical sites or areas of infection will 'light up' on an FDG scan, just like cancer. If a patient just had surgery, the doctor may wait 4-6 weeks before doing a PET scan to avoid a false-positive result.

There is no known cross-sensitivity between Fludeoxyglucose F-18 and iodinated contrast media (used in CT scans) or gadolinium (used in MRI). Patients allergic to 'CT dye' can safely receive Fludeoxyglucose F-18, as they are chemically unrelated.

> Important: Your healthcare provider will evaluate your complete medical history and current metabolic state before prescribing Fludeoxyglucose F-18.

Fludeoxyglucose F-18 is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether FDG can cause fetal harm. However, it is well-established that ionizing radiation is potentially harmful to a developing fetus. The risk is highest during the period of organogenesis (first trimester). If a PET scan is absolutely necessary for a pregnant woman (e.g., for aggressive lymphoma), the dose may be minimized, and the patient is encouraged to hydrate and void frequently to move the radiation away from the pelvic area.

Fludeoxyglucose F-18 is excreted in human breast milk. To minimize the risk of radiation exposure to the nursing infant, a 'pump and dump' period is recommended. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) typically suggests interrupting breastfeeding for at least 12 hours after the injection. During this time, milk should be expressed and discarded. By 12 hours, more than 98% of the radioactivity will have decayed.

FDG is approved for use in children for oncology, neurology (epilepsy), and certain inflammatory conditions. Pediatric patients are more sensitive to radiation than adults because their tissues are rapidly dividing and they have a longer remaining life span in which to develop a radiation-induced cancer. Therefore, pediatric doses are strictly weight-based. Children may also require sedation to remain still during the uptake and imaging periods.

Clinical studies have not identified significant differences in safety or effectiveness between elderly and younger patients. However, the elderly are more likely to have reduced renal function. Since the tracer is cleared through the urine, elderly patients should be monitored for adequate hydration. There is no increased 'fall risk' directly from the drug, but the required fasting may cause orthostatic hypotension (dizziness upon standing) in older adults.

In patients with renal impairment, the physical half-life of the tracer remains 110 minutes, but the biological clearance is delayed. This results in a higher radiation dose to the kidneys and bladder. No specific dose reduction is mandated, but the 'ALARA' principle is applied, and post-scan hydration is critical. For patients on dialysis, the scan should ideally be performed on a day when dialysis is scheduled shortly after the procedure to help clear the tracer.

No dosage adjustments are needed for patients with liver disease. The liver's metabolic capacity does not affect the 'metabolic trapping' mechanism of FDG-6-phosphate.

> Important: Special populations require individualized medical assessment. Always inform the imaging staff if you are pregnant, nursing, or have kidney disease.

Fludeoxyglucose F-18 is a glucose analog. It is transported into cells by GLUT-1 and GLUT-3 transporters. Once intracellular, it is phosphorylated by the enzyme hexokinase (specifically Hexokinase II in many tumors) into 18F-FDG-6-phosphate. Because the 2-carbon hydroxyl group of glucose has been replaced by a Fluorine-18 atom, the molecule cannot undergo further glycolysis or be converted into glycogen. It is also a poor substrate for glucose-6-phosphatase, the enzyme that would normally allow it to exit the cell. This results in 'metabolic trapping,' where the radioactivity accumulates in proportion to the cell's rate of glucose consumption.

Fludeoxyglucose F-18 has no significant pharmacodynamic effects at the doses used for imaging. It does not alter blood pressure, heart rate, or blood glucose levels. Its only 'effect' is the emission of radiation. The time to onset for optimal imaging is 30–60 minutes, which is the time required for the tracer to accumulate in target tissues and clear from the background blood pool. The duration of the 'effect' is limited by the 110-minute physical half-life of the isotope.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | Negligible |

| Physical Half-life | 109.8 minutes |

| Biological Half-life | ~2 hours (Renal) |

| Tmax (Uptake) | 30 - 90 minutes |

| Metabolism | Phosphorylation (not CYP) |

| Excretion | Renal (20% in 2 hours) |

• Molecular Formula: C6H11(18F)O5
• Molecular Weight: 181.15 g/mol
• Solubility: Highly soluble in water and 0.9% sodium chloride.
• Structure: A glucose ring structure where the hydroxyl group at the C-2 position is replaced by a radioactive Fluorine-18 atom.

Fludeoxyglucose F-18 is classified as a Radioactive Diagnostic Agent and a Radiopharmaceutical. It is the 'gold standard' tracer for Positron Emission Tomography (PET). Related medications include other F-18 labeled tracers like Florbetapir (for amyloid plaques) or Fluciclovine (for prostate cancer), though FDG remains the most widely used due to its broad application in oncology.